Angiographic follow-up at 9 months showed significantly less late lumen loss in the everolimus group ( in-segment , 0.52 [ standard deviation , 0.58 ) mm vs -0.05 [ 0.32 ] mm ; in-stent , 0.76 [ 0.54 ] mm vs 0.13 [ 0.31 ] mm ; P < .0001 ) .